Search results
Results from the WOW.Com Content Network
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare giant is dealing with the fast-approaching patent cliff for its most ...
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in this pharmaceutical giant's success is its Keytruda immunotherapy drug ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
For premium support please call: 800-290-4726 more ways to reach us
This makes it worthwhile to examine what the stock has in store. Recently, Zacks.com users have been paying close attention to Merck (MRK). ... News. Search. Need help? Call us! 800-290-4726 ...